Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...